Hyperfine (Nasdaq:HYPR) announced that it made the first commercial sales of its next-generation Swoop system powered by new ...

Nuwellis terminated its REVERSE‑HF randomized trial comparing ultrafiltration with IV loop diuretics in hospitalized heart ...

Stereotaxis announced that it entered into definitive agreements with investors to sell approximately $12.5 million in common stock.

UroMems received FDA investigational device exemption (IDE) approval to begin a first-of-its-kind trial for its smart implant.

NanoVibronix (Nasdaq:NAOV) today announced that it entered into a definitive agreement to sell up to $50 million in stock.